Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.

On the evening of August 27, Yaoyigou disclosed that its chairman and general manager, Chen Shunjun, resigned from his posts as chairman, director, general manager, chairman of the strategy and development committee, and member of the remuneration and assessment committee, after omitting related-party information provided to the company and its auditors. Chen's original term was set to run from July 30, 2025, until the end of the fourth board of directors' term. After resigning, he no longer holds other senior management positions, but remains at the company focusing on innovative growth-side business. Yaoyigou is the first listed pharmaceutical industry internet company in China. In 2025, it recorded its first annual loss since listing, with net profit attributable to the parent company of minus 12.85 million yuan. In the first half of 2026, the loss widened year-on-year to minus 9.527 million yuan. In the secondary market, the company's share price has been volatile this year, closing at 25.22 yuan per share on August 27.

Yaoyigou released its 2026 interim report, with net profit attributable to the parent company at negative 9.5268 million yuan, a loss expansion of 278,400 yuan compared with the same period last year. The company's total operating revenue was 2.181 billion yuan, and net cash inflow from operating activities was 7.1471 million yuan. The latest asset-liability ratio was 59.30%, up 1.68 percentage points from the previous quarter and up 6.13 percentage points from the same period last year. The latest gross margin was 9.17%, down 0.98 percentage points from the previous quarter and down 1.65 percentage points from the same period last year. The latest ROE was negative 1.17%, down 0.26 percentage points from the same period last year. The company's diluted earnings per share was negative 0.10 yuan.